Clinical trials: PPA
Filamentary Keratitis
Mucinex® for Treatment of Filamentary Keratitis
It is a pilot study aimed to determine if oral Mucinex® is effective in reducing the amount of corneal filaments and improving symptomology in subjects with filamentary keratitis.
- Trial name
- NCT02859246
- Testing
- Mucinex®
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Atherosclerosis of Native Arteries of the Extremities
Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project
To determine whether the Boston Scientific nitinol drug-eluting stent shows acceptable performance at 9 months when treating Superficial Femoral (SFA) and/or Proximal Popliteal Artery (PPA) lesions.
- Trial name
- MAJESTIC (NCT01820637)
- Testing
- The Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA)
- Where
- 13 sites in Australia, Austria and 3 more
- Volunteers
- 57 people
- Sponsor
- Boston Scientific Corporation
Arterial Occlusive Diseases, Atherosclerosis
Trial Comparing ELUVIA Versus Bare Metal Stent in Treatment of Superficial Femoral and/or Proximal Popliteal Artery
The EMINENT study is a prospective, multi-center study evaluating the effectiveness of the ELUVIA stent versus Self-Expanding Bare Nitinol Stents in the treatment of lesions in the femoropopliteal arteries.
- Conditions
- Arterial Occlusive Diseases, Atherosclerosis, Vascular Diseases, Arteriosclerosis
- Trial name
- EMINENT (NCT02921230)
- Testing
- Peripheral stenting
- Where
- 60 sites in Austria, Belgium and 8 more
- Volunteers
- 775 people
- Sponsor
- Boston Scientific Corporation
Chronic Rhinitis
The Effect of Oral Guaifenesin on Pediatric Chronic Rhinitis: A Pilot Study
This is a 14-day, randomized, placebo-controlled, parallel group, masked clinical trial of oral guaifenesin for the therapy of Chronic Rhinitis (CRS) in 36 children between the ages of 7 and 18 years.
- Trial name
- NCT01364467
- Testing
- Guaifenesin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Virginia Commonwealth University
Amyotrophic Lateral Sclerosis, Frontal Temporal Dementia
Therapy in Amyotrophic Lateral Sclerosis (TAME)
The purpose of this study is to determine if memantine at up to 20 mg twice a day when used in conjunction with riluzole, can slow down the disease progression of patients with ALS including potentially improving their…
- Trial name
- TAME (NCT02118727)
- Testing
- Memantine
- Where
- 13 sites in United States
- Volunteers
- 89 people
- Sponsor
- University of Kansas Medical Center
Niemann-Pick Disease, Type C
N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC)
This is a multinational, multicenter, open-label, rater-blinded prospective Phase II study which will assess the safety and efficacy of N-Acetyl-L-Leucine (IB1001) for the treatment of Niemann-Pick type C disease (NPC).
- Trial name
- NCT03759639
- Testing
- IB1001
- Where
- 9 sites in United States, Germany and 3 more
- Volunteers
- 33 people
- Sponsor
- IntraBio Inc
Niemann-Pick Disease, Type C
Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease
Due to different study designs, the sponsor separated Part C into this separate registration (NCT04958642), leaving Parts A/B in NCT02534844.
- Trial name
- NCT04958642
- Testing
- Adrabetadex
- Where
- 30 sites in United States, Australia and 7 more
- Volunteers
- 66 people
- Sponsor
- Mandos LLC
Frontotemporal Dementia, Right Sided Cerebral Hemisphere Cerebrovascular Accident
Efficacy of Web-Based Social-Cognitive Interventions in Right Hemisphere Stroke and Frontotemporal Dementia
This study is being done to test the feasibility and effectiveness of web-based social-cognitive training exercises in treating social-emotional deficits in patients with stroke or frontotemporal dementia (FTD).
- Trial name
- NCT02506036
- Testing
- Brain HQ
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Johns Hopkins University
Lysosomal Acid Lipase Deficiency, Wolman Disease
Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency
This was an open-label, repeat-dose, intra-participant dose-escalation study of SBC-102 (sebelipase alfa) in children with growth failure due to lysosomal acid lipase (LAL) Deficiency.
- Trial name
- NCT01371825
- Testing
- Sebelipase alfa (SBC-102)
- Where
- 7 sites in United States, Egypt and 3 more
- Volunteers
- 9 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Niemann-Pick Disease, Type C
Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C
Niemann-Pick disease, type C (NPC) is a lethal, autosomal recessive, lysosomal storage disorder characterized by neurodegeneration in early childhood and death in adolescence.
- Trial name
- NCT03471143
- Testing
- VTS-270
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Washington University School of Medicine
Atherosclerosis
Jetstream in Treatment of Occlusive Atherosclerotic Lesions in the SFA and/or PPA
This clinical study is a prospective, non-randomized, multicenter, single-arm study to demonstrate the acceptable safety and performance of the JETSTREAM™ Atherectomy System (Jetstream) used during percutaneous peripheral…
- Trial name
- NCT03455855
- Testing
- Jetstream System
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Boston Scientific Corporation
Frontotemporal Dementia
A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)
A Phase 2 open label study evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AL001 in participants with a Granulin mutation or C9orf72 mutation causative of frontotemporal dementia.
- Trial name
- NCT03987295
- Testing
- AL001
- Where
- 12 sites in United States, Canada and 4 more
- Volunteers
- 33 people
- Sponsor
- Alector Inc.
Neimann-Pick Disease
Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1
Niemann-Pick disease type C (NPC) is a lethal, autosomal recessive, lysosomal storage disorder characterized by neurodegeneration in early childhood and death in adolescence.
- Trial name
- NCT02124083
- Testing
- Vorinostat
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Primary Progressive Aphasia, Behavioral Variant of Frontotemporal Dementia
Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and Frontotemporal Dementia
This study is designed to learn more about overall tau burden in the brain of patients with Primary Progressive Aphasia (PPA) and Frontotemporal Dementia.
- Conditions
- Primary Progressive Aphasia, Behavioral Variant of Frontotemporal Dementia, Frontotemporal Dementia, Behavioral Variant
- Trial name
- SLD3 (NCT02736695)
- Testing
- F-18 AV 1451
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Mayo Clinic
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease
This study seeks to evaluate the efficacy and safety of ABBV-8E12 in participants with early Alzheimer's disease (AD).
- Trial name
- NCT02880956
- Testing
- ABBV-8E12
- Where
- 68 sites in United States, Australia and 9 more
- Volunteers
- 453 people
- Sponsor
- AbbVie
Frontotemporal Dementia, Behavioral Variant
Intranasal Insulin in Frontotemporal Dementia (FTD)
This project will study intranasal (IN) insulin in Frontotemporal dementia (FTD) in 12 patients. Study Investigators aim to evaluate the feasibility of the EXAMINER cognitive battery as a cognitive outcome measure in FTD, the…
- Trial name
- NCT04115384
- Testing
- Novolin-R insulin
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- HealthPartners Institute
Healthy Subjects
Study to Evaluate Drug-drug Interactions of Guaifenesin and Hydrocodone Bitartrate
Determine and compare the plasma concentrations and safety and tolerability of Guaifenesin and hydrocodone bitartrate when they are administered alone or in combination to normal healthy male and/or female subjects.
- Trial name
- NCT03642873
- Testing
- Humibid®, Hydrocodone Bitartrate, Humibid® and Hydrocodone Bitartrate tablet
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Reckitt Benckiser LLC
Common Cold, Cough
A Clinical Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin
The purpose of this Real-World Evidence study is to generate real world data from participants with cough associated with the common cold, evaluating the effects in two arms with commercially available cough syrups on…
- Trial name
- NCT06716645
- Testing
- Robitussin Maximum Strength Cough and Chest Congestion DM, Robitussin Maximum Strength Nighttime Cough DM
- Where
- United States
- Volunteers
- 244 people
- Sponsor
- HALEON
Alzheimer Disease
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's Disease
- Trial name
- NCT05063539
- Testing
- LY3372689
- Where
- 69 sites in United States, Australia and 3 more
- Volunteers
- 327 people
- Sponsor
- Eli Lilly and Company
Atherosclerosis of Native Arteries of the Extremities, Unspecified
SuperNOVA Clinical Stenting Trial
The primary objective of this clinical study is to determine whether the Innova Stent System shows acceptable performance in long-term (12-month) safety rates and vessel patency when treating femoropopliteal lesions.
- Trial name
- NCT01292928
- Testing
- Stent implantation
- Where
- 49 sites in United States, Austria and 5 more
- Volunteers
- 299 people
- Sponsor
- Boston Scientific Corporation